LSH Partners served as financial advisor to Reprotech LLC on its strategic business combination with TMRW Life Sciences (“TMRW”).  The combination brings together two leaders in fertility storage and technology to create the industry's most comprehensive, technology-enabled company for the management and cryostorage of frozen eggs, embryos, and sperm. The combined business will operate under the Reprotech banner, which will now feature the TMRW, Matcher, and Cryologix brands. Together, the combined organization will safeguard more than one million fertility specimens, partner with approximately 75% of fertility centers nationwide, support more than 50% of U.S. patient cycles, and operate eight offsite storage facilities.

"There is clear industrial logic in bringing Reprotech and TMRW together," said Luis A. Fernandez, Chairman of the Board of Reprotech. "We are building a company designed to meet the evolving demands of the fertility industry by combining state of the art infrastructure, trusted service, and next-generation technology. Following our investment in IMT Matcher and now with TMRW's Digital Specimen Management platform, we are creating a fully technology-enabled cryostorage offering that can meet clinics where they are today while helping define where the industry is going tomorrow." ¹

About Reprotech:

Reprotech is the leading provider of products and services for the safe-guarding, management and long-term storage of reproductive specimens. Reprotech's integrated portfolio includes five purpose-built biorepositories across the U.S., advanced cryostorage management technologies and global digital chain-of-custody solutions. Reprotech partners with fertility centers to reduce specimen storage burden and liability, streamline billing and consent management, strengthen traceability, and manage risk.

About TMRW Life Sciences:

Founded in 2018, TMRW Life Sciences, Inc. is a fertility technology company digitizing the IVF lab with the world's first automated platform for the safe management and storage of frozen sperm, eggs, and embryos. For the first time, frozen specimens can be digitally identified and tracked, safely managed with automated robotics, and remotely monitored around the clock. TMRW's next-generation technology platforms set a new standard of care by reducing potential points of failure associated with manual systems.

¹ Press Release dated April 2, 2026, Reprotech and TMRW Life Sciences enter into Business Combination to Create the Most Comprehensive Technology-Enabled Cryostorage Company in Fertility.